Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

209P_PR - Understanding patient experience in Europe: the first Global Lung Cancer Coalition Patient Experience Survey


24 Mar 2021


e-Poster Display Session


Vanessa Beattie


Journal of Thoracic Oncology (2021) 16 (suppl_4): S807-S814.


V. Beattie1, W. Boerckel2, M. Rigney3, K. O'Hagan4, M. Hennink5, J. Fox6

Author affiliations

  • 1 Lung Cancer Nursing UK, Solihull/GB
  • 2 Cancer Care, 11791 - New York/US
  • 3 GO2Foundation, 20035 - Washington/US
  • 4 Irish Cancer Society, D04 VX65 - Dublin/IE
  • 5 Patient, NotApplicable/NL
  • 6 Roy Castle Lung Cancer Foundation, L3 9LQ - Liverpool/GB

Abstract 209P_PR


Little comparative European or global data exists on lung cancer patient experience. The Global Lung Cancer Coalition (GLCC), a partnership of 40 patient organisations across 29 nations, wanted to understand the experiences of lung cancer patients, identifying common themes and differences between countries. The GLCC therefore used its member networks to run a multi-national online survey of patients – the first time this had been attempted.


The GLCC convened a steering group with members from the UK, Ireland, and the Netherlands, including patients, clinicians and advocates. 10 questions were agreed and translated into multiple languages with appropriate terminology. As well as demographic questions, participants were asked what treatments they had received, whether they felt involved in decisions and were treated with dignity and respect, and how they describe themselves. The survey was distributed by GLCC members via emails, newsletters and social media. The results were collated and analysed by the steering group. The GLCC produced a global report with findings for all participating countries, as well as bespoke briefings comparing the perspectives of patients in each country to those of global respondents, for national campaigning.


Nine of the 17 countries that took part are in Europe: Bulgaria, Czech Republic, Denmark, Ireland, Netherlands, Portugal, Spain, Sweden and the UK. 574 of 907 patients who responded were from Europe (63%). Headline European findings include: 11% of respondents did not know what type of lung cancer they had (13% globally) 19% of respondents stated they did not feel involved in decisions about their treatment and care (18% globally) 11% felt they had ‘never’ or only ‘sometimes’ been treated with dignity and respect by their treatment team (9% globally).


The survey demonstrates that a pan-European patient experience survey can take place. It also suggests more could be done across nations to improve lung cancer patients’ experience, particularly involvement in decisions around treatment and care. We are grateful to all the patients who responded and shared their experiences.

Editorial acknowledgement

The abstract was written by Incisive Health as policy and communications experts. All editorial control was retained by the authors.

Legal entity responsible for the study

The authors.


The Global Lung Cancer Coalition (GLCC) receives funding for its work from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche and Takeda Oncology.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings